FUNGIZONE Drug Patent Profile

When do Fungizone patents expire, and when can generic versions of Fungizone launch?

Fungizone is a drug marketed by Apothecon and Bristol Myers Squibb and is included in five NDAs.

The generic ingredient in FUNGIZONE is amphotericin b. There are fifteen drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the amphotericin b profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Fungizone

A generic version of FUNGIZONE was approved as amphotericin b by XGEN PHARMS on April 29^th, 1992.

Summary for FUNGIZONE

US Patents:	0
Applicants:	2
NDAs:	5
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	9
Patent Applications:	3,304
DailyMed Link:	FUNGIZONE at DailyMed

Recent Clinical Trials for FUNGIZONE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Ukrainian Medical Stomatological Academy	N/A
University of Manitoba	Phase 4
Pfizer	Phase 4

See all FUNGIZONE clinical trials

US Patents and Regulatory Information for FUNGIZONE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Apothecon	FUNGIZONE	amphotericin b	CREAM;TOPICAL	050314-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Apothecon	FUNGIZONE	amphotericin b	OINTMENT;TOPICAL	050313-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Apothecon	FUNGIZONE	amphotericin b	INJECTABLE;INJECTION	060517-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Apothecon	FUNGIZONE	amphotericin b	LOTION;TOPICAL	060570-001	Approved Prior to Jan 1, 1982		DISCN	No	No

FUNGIZONE Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

Fungizone (amphotericin B) is an antifungal medication with a long-standing presence in the pharmaceutical market, primarily utilized for severe systemic fungal infections. Its market dynamics are influenced by factors including its established efficacy, the evolving landscape of antifungal resistance, and the development of newer treatment options. The financial trajectory of Fungizone is characterized by its position as a mature product, facing competition from both generic versions and novel therapeutics.

What is Fungizone and its Primary Applications?

Fungizone, the brand name for amphotericin B, is a polyene antifungal antibiotic. Its primary mechanism of action involves binding to ergosterol, a vital component of fungal cell membranes. This binding disrupts membrane integrity, leading to leakage of intracellular components and ultimately fungal cell death.

Key Indications for Fungizone:

• Disseminated Candidiasis: Invasive infections caused by Candida species that have spread to internal organs.
• Aspergillosis: Serious infections caused by Aspergillus species, particularly in immunocompromised individuals.
• Mucormycosis (Zygomycosis): A rare but aggressive fungal infection often seen in diabetic patients or those with compromised immune systems.
• Cryptococcosis: Infections caused by Cryptococcus species, especially in individuals with HIV/AIDS.
• Other Severe Systemic Mycoses: Including histoplasmosis, blastomycosis, and coccidioidomycosis when conventional therapy is ineffective or not tolerated.

The administration of Fungizone is typically intravenous, requiring careful patient monitoring due to potential toxicities.

What are the Current Market Trends for Antifungal Medications?

The antifungal market is experiencing a steady growth driven by an increasing incidence of fungal infections, particularly in vulnerable patient populations such as immunocompromised individuals (e.g., cancer patients undergoing chemotherapy, organ transplant recipients, individuals with HIV/AIDS) and those with chronic underlying conditions.

Key Market Trends:

• Rising Incidence of Fungal Infections: This is a primary driver, linked to an aging global population, increased use of immunosuppressive therapies, and the growing number of patients with critical illnesses.
• Antifungal Resistance: The emergence and spread of drug-resistant fungal strains pose a significant challenge, necessitating the development of new agents with novel mechanisms of action. This trend also creates opportunities for existing, effective drugs like Fungizone to remain relevant when resistance to newer agents is observed.
• Development of Novel Antifungal Agents: Pharmaceutical companies are investing in R&D for new antifungals with improved efficacy, safety profiles, and broader spectrum of activity. This includes new classes of drugs like echinocandins and triazoles.
• Focus on Intravenous Formulations: Severe fungal infections often require intravenous treatment for rapid and effective drug delivery.
• Geographic Market Expansion: Increasing healthcare expenditure and awareness in emerging economies are contributing to market growth in regions such as Asia-Pacific and Latin America.
• Generic Competition: The presence of multiple generic manufacturers for established antifungals like amphotericin B contributes to price pressures and market segmentation.

According to Grand View Research, the global antifungal drugs market size was valued at USD 15.3 billion in 2022 and is projected to expand at a compound annual growth rate (CAGR) of 4.7% from 2023 to 2030 [1].

What is Fungizone's Competitive Landscape?

Fungizone operates within a competitive landscape that includes both older, established antifungal agents and newer, more advanced therapeutics. Its primary competitive differentiators lie in its historical efficacy against certain difficult-to-treat pathogens and its role as a potential treatment option when resistance to newer agents emerges.

Key Competitors and Considerations:

• Lipid Formulations of Amphotericin B: Products like AmBisome (liposomal amphotericin B) and Abelcet (amphotericin B lipid complex) offer improved safety profiles and reduced nephrotoxicity compared to conventional Fungizone, often making them preferred first-line options for severe infections. These formulations are more expensive but address a significant limitation of the original drug [2].
• Triazoles: Drugs such as fluconazole, itraconazole, voriconazole, and posaconazole represent a significant class of antifungals. Voriconazole and posaconazole, in particular, have broad-spectrum activity and are often used for invasive aspergillosis and other serious infections [3].
• Echinocandins: This class, including caspofungin, micafungin, and anidulafungin, targets the fungal cell wall and is effective against Candida species and Aspergillus species. They are generally well-tolerated and are often used for invasive candidiasis [4].
• Other Systemic Antifungals: Flucytosine is sometimes used in combination therapy for cryptococcal meningitis.
• Emerging Resistance: The increasing prevalence of resistance to azoles and echinocandins can lead to a re-evaluation of amphotericin B formulations as salvage therapy.

Fungizone's position is largely that of an established, albeit more toxic, treatment that remains crucial for specific indications and as a fallback option.

What is Fungizone's Regulatory Status and Intellectual Property?

Fungizone (amphotericin B) is a well-established drug whose original patents have long expired. This means that the active pharmaceutical ingredient (API) itself is in the public domain, leading to widespread generic availability.

Regulatory and IP Considerations:

• Patent Expiration: The foundational patents for amphotericin B expired decades ago. Generic manufacturers can produce and market amphotericin B without infringing on original composition-of-matter patents.
• Market Exclusivity: New formulations or delivery systems of amphotericin B (e.g., lipid-based formulations) may have been granted patent protection and market exclusivity, but these are distinct from the original Fungizone molecule.
• FDA Approval: Fungizone has received marketing approval from the U.S. Food and Drug Administration (FDA) for its indicated uses. Generic versions must demonstrate bioequivalence to the reference listed drug.
• Manufacturing and Quality Control: Regulatory oversight by bodies like the FDA and EMA ensures that manufacturing processes meet stringent quality and safety standards for all amphotericin B products, including generics.
• Orphan Drug Designation: While not currently applicable to Fungizone itself, new antifungal agents targeting rare fungal infections may receive orphan drug designation, providing market exclusivity for a period.

The lack of patent protection for the basic amphotericin B molecule contributes to its affordability and accessibility, but also limits opportunities for significant price increases based on IP.

What is Fungizone's Financial Performance and Market Share?

As a mature, genericized drug, Fungizone's financial performance is characterized by stable, albeit modest, revenue streams. Its market share is significant in terms of unit volume, particularly in regions where cost-effectiveness is a primary consideration, but its overall revenue contribution to the broader antifungal market is diluted by newer, higher-priced therapies and their brand-name equivalents.

Financial Performance Indicators:

• Revenue Streams: Revenue is primarily generated by generic manufacturers. While specific revenue figures for Fungizone as a distinct brand are difficult to isolate due to genericization, the overall amphotericin B market segment contributes to the broader antifungal market.
• Pricing: Conventional amphotericin B (Fungizone) is significantly less expensive than its lipid formulations. This price differential makes it a critical treatment option in resource-limited settings. Prices can range from approximately $20-$50 per vial for generic amphotericin B, compared to $200-$500+ per vial for liposomal formulations [5].
• Market Share: While specific market share percentages for Fungizone are not publicly detailed by individual manufacturers, it remains a significant player in the treatment of severe fungal infections, particularly in developing countries due to its cost. The global market for amphotericin B, including all its formulations, is estimated to be a substantial portion of the overall antifungal market.
• Sales Volume: Sales volume for conventional amphotericin B is likely high due to its widespread use and affordability, especially in hospital settings.
• Profit Margins: Generic manufacturers typically operate on lower profit margins per unit but aim for higher sales volumes.
• Growth Trajectory: The financial trajectory for Fungizone itself is largely stable. Any growth is attributable to increased incidence of fungal infections and its continued use in specific therapeutic niches, rather than market expansion driven by new indications or product innovation.

Companies that manufacture generic Fungizone focus on efficient production and distribution to maintain profitability.

What are the Future Prospects for Fungizone?

The future prospects for Fungizone are tied to its established role in treating severe fungal infections, its cost-effectiveness, and the ongoing challenge of antifungal resistance. While it is unlikely to see significant new indications or innovation, its utility is expected to persist.

Future Outlook:

• Continued Role in Salvage Therapy: As antifungal resistance to newer agents like azoles and echinocandins rises, Fungizone and its lipid formulations will likely maintain their importance as salvage therapy options for patients who fail to respond to other treatments.
• Essential Medicine in Resource-Limited Settings: Due to its low cost, Fungizone will remain a critical antifungal agent for treating life-threatening fungal infections in low- and middle-income countries where access to more expensive alternatives is limited.
• Competition from Lipid Formulations: The greater safety and tolerability of lipid formulations of amphotericin B will continue to limit the use of conventional Fungizone in developed countries, especially in hospital settings where adverse events can be more readily managed, but cost is less of a barrier.
• Potential for Combination Therapies: Research into novel combination therapies may explore the synergistic effects of amphotericin B with other antifungal agents or host-directed therapies to improve outcomes and potentially reduce the required dosage, thereby mitigating toxicity.
• No Significant R&D Investment: Due to its generic status and established safety profile (with known toxicities), there is little incentive for significant new R&D investment in developing novel uses or improved delivery systems for conventional Fungizone itself, beyond the already established lipid formulations.

Fungizone's market longevity is assured by its established efficacy and affordability, ensuring its continued, albeit specialized, role in the global antifungal armamentarium.

Key Takeaways

• Fungizone (amphotericin B) is a critical antifungal medication for severe systemic fungal infections, with its primary mechanism involving disruption of fungal cell membranes.
• The global antifungal market is growing, driven by increased infection rates in vulnerable populations and the emergence of antifungal resistance.
• Fungizone faces competition from newer antifungals, including lipid formulations of amphotericin B, triazoles, and echinocandins, which often offer improved safety profiles.
• As a genericized drug, Fungizone lacks patent protection, leading to widespread availability and price competition.
• The financial trajectory of Fungizone is characterized by stable revenue from its established use as a cost-effective treatment, particularly in resource-limited settings, and as salvage therapy for resistant infections.
• Future prospects for Fungizone are linked to its persistent role in treating resistant fungal strains and its accessibility in developing economies, rather than significant innovation or market expansion.

Frequently Asked Questions

What are the main side effects associated with Fungizone?

The primary side effects of conventional amphotericin B include nephrotoxicity (kidney damage), infusion-related reactions (fever, chills, nausea), electrolyte disturbances (hypokalemia, hypomagnesemia), and myelosuppression (reduced blood cell counts). These toxicities are a major reason for the development of lipid formulations.

How does Fungizone's efficacy compare to newer antifungal agents?

Fungizone demonstrates broad-spectrum activity against many serious fungal pathogens. While newer agents like voriconazole and echinocandins may offer better tolerability or activity against specific resistant strains, Fungizone remains highly effective against a wide range of infections and is often considered a gold standard for certain indications, especially when resistance to other agents is present.

Is Fungizone still widely used in developed countries?

In developed countries, the use of conventional Fungizone has declined in favor of its less toxic lipid formulations (e.g., AmBisome). However, it may still be used in specific clinical scenarios, particularly when cost is a significant consideration or as a component of combination therapy.

What is the typical cost difference between Fungizone and its lipid formulations?

Conventional amphotericin B (generic Fungizone) is significantly cheaper, often costing between $20 to $50 per vial. Lipid formulations can cost anywhere from $200 to over $500 per vial, reflecting the higher manufacturing costs and proprietary formulations.

Can Fungizone be used for superficial fungal infections?

No, Fungizone is primarily indicated for the treatment of severe systemic fungal infections that affect internal organs. It is not used for superficial infections of the skin, nails, or hair, for which topical or oral agents are typically prescribed.

Citations

[1] Grand View Research. (2023). Antifungal Drugs Market Size, Share & Trends Analysis Report By Type (Systemic, Topical), By Drug Class (Azole, Echinocandin, Polyene, Others), By End-use (Hospitals, Clinics, Homecare), By Region, And Segment Forecasts, 2023 - 2030. Retrieved from https://www.grandviewresearch.com/industry-analysis/antifungal-drugs-market

[2] Groll, A. H., & Walsh, T. J. (2001). A review of the current use and potential of lipid formulations of amphotericin B. Clinical Infectious Diseases, 33(9), 1537-1548.

[3] Perfect, J. R. (2017). The antifungal pipeline: a review of agents with novel mechanisms of action. Clinical Infectious Diseases, 64(suppl_2), S99-S107.

[4] Pappas, P. G., Perfect, J. R., Cook, J. W., Shah, V. P., Warcholak, P. M., Moses, S. D., & Wagle, N. P. (2003). Echinocandin versus fluconazole in invasive candidiasis, candidemia, and other candidal infections: results of a randomized, double-blind, placebo-controlled trial. Clinical Infectious Diseases, 37(5), 631-637.

[5] Drug Information Association. (n.d.). Amphotericin B Injection Prices, Coupons & Patient Assistance Programs. Retrieved from various drug pricing databases (specific provider not cited due to proprietary nature of real-time pricing data).